{
    "root": "3bf54f0a-da37-45d8-8b9f-74e474bf009e",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Clonazepam",
    "value": "20250305",
    "ingredients": [
        {
            "name": "CLONAZEPAM",
            "code": "5PE9FDE8GB"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "D&C YELLOW NO. 10",
            "code": "35SW5USQ3G"
        }
    ],
    "indications": "clonazepam useful alone adjunct treatment lennox-gastaut syndrome ( petit mal variant ) , akinetic , myoclonic seizures . patients absence seizures ( petit mal ) failed respond succinimides , clonazepam may useful . loss effect may occur course clonazepam treatment ( : loss effect ) .",
    "contraindications": "clonazepam available tablet . tablets administered water swallowing tablet whole .",
    "warningsAndPrecautions": "clonazepam tablets , usp available : 0.5 mg : light yellow , flat-faced beveled edge tablets , scored , debossed `` 2530 `` one side debossed `` v `` reverse side , available follows : bottles 20 : ndc 68788-8420-2 bottles 30 : ndc 68788-8420-3 bottles 60 : ndc 68788-8420-6 bottles 90 : ndc 68788-8420-9",
    "adverseReactions": "clonazepam contraindicated patients following conditions : \u2022history sensitivity benzodiazepines \u2022clinical biochemical evidence significant liver disease \u2022acute narrow angle glaucoma ( may used patients open angle glaucoma receiving appropriate therapy ) .",
    "indications_original": "Clonazepam is useful alone or as an adjunct in the treatment of the Lennox-Gastaut syndrome (petit mal variant), akinetic, and myoclonic seizures. In patients with absence seizures (petit mal) who have failed to respond to succinimides, clonazepam may be useful.\n                        Some loss of effect may occur during the course of clonazepam treatment (see \n                              PRECAUTIONS: Loss of Effect\n                           ).",
    "contraindications_original": "Clonazepam is available as a tablet. The tablets should be administered with water by swallowing the tablet whole.",
    "warningsAndPrecautions_original": "Clonazepam Tablets, USP are available as:\n                  0.5 mg: light yellow, flat-faced beveled edge tablets, scored, debossed \"2530\" on one side and debossed \"V\" on the reverse side, available as follows:\n                  \n                     \n                        \u00a0Bottles of 20: NDC 68788-8420-2\n                     \n                        \u00a0Bottles of 30: NDC 68788-8420-3\n                     \n                        \u00a0Bottles of 60: NDC 68788-8420-6\n                     \n                        \u00a0Bottles of 90: NDC 68788-8420-9",
    "adverseReactions_original": "Clonazepam is contraindicated in patients with the following conditions:\n                  \n                     \n                        \u2022History of sensitivity to benzodiazepines\n                     \n                        \u2022Clinical or biochemical evidence of significant liver disease\n                     \n                        \u2022Acute narrow angle glaucoma (it may be used in patients with open angle glaucoma who are receiving appropriate therapy)."
}